伊索林科菲林抑制NLRP3炎症酶并改善孕期糖尿病
1Department of Gynecology and Obstetrics, The Fourth Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215000, China.
Archivum immunologiae et therapiae experimentalis
|March 18, 2025
概括
伊索林科菲林 (IRN) 在妊娠糖尿病 (GDM) 的小鼠中有效改善了血糖和胰岛素耐受性. 此外,IRN还降低了胎盘炎症和氧化应激,促进更健康的胎儿发育,并可能有利于GDM管理.
科学领域:
- 生殖生物学 生殖生物学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 孕期糖尿病 (GDM) 对母亲和胎儿的健康构成风险.
- 目前的GDM治疗有局限性,需要新的治疗策略.
- 伊索林科菲林 (IRN) 是GDM干预的潜在候选者.
研究的目的:
- 为了研究异黄素 (IRN) 对妊娠糖尿病 (GDM) 的治疗效果.
- 阐明GDM中IRN作用的基本机制,重点关注炎症和氧化应激.
- 评估IRN对母亲代谢参数和胎儿结果的影响.
主要方法:
- 使用db/+小鼠模型进行GDM诱导.
- 向GDM小鼠施用不同剂量的IRN (20 mg/kg,40 mg/kg).
- 通过腹腔内葡萄糖和胰岛素耐受性测试 (IPGTT,IPITT) 评估葡萄糖代谢.
- 量化了胎盘炎症,氧化应激标志物和NLRP3炎症酶活性,使用ELISA,免疫阻塞和生物化学测试.
主要成果:
- 在GDM小鼠中,IRN显著改善了血糖水平和胰岛素耐受性.
- 通过IRN治疗显著减少了胎盘炎症 (TNF-α,IL-6,IL-1β) 和氧化应激 (MDA,SOD,GPx,GSH).
- IRN的使用导致后代出生体重增加,并抑制了NLRP3炎症酶激活.
结论:
- 伊索林科菲林 (IRN) 显示出在管理GDM方面具有显著的治疗潜力.
- 通过NF-κB/NLRP3通路,IRN可以缓解与GDM相关的胎盘炎症和氧化应激.
- 在GDM模型中,IRN治疗改善了母亲的代谢健康,并增强了胎儿的发育.
更多相关视频
07:13Induction of Maternal Immune Activation in Mice at Mid-gestation Stage with Viral Mimic PolyI:C
Published on: March 25, 2016
18.2K
09:09Generating a Reproducible Model of Mid-Gestational Maternal Immune Activation using PolyI:C to Study Susceptibility and Resilience in Offspring
Published on: August 17, 2022
1.5K
相关概念视频
Pathophysiology of Diabetes
837
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
837
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Glucagon-like Receptor Agonists
280
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
280
Oral Hypoglycemic Agents: Glinides
120
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
120
Dipeptidyl Peptidase 4 Inhibitors
148
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
148
